DOUBLE DOSE - Teva Pharmaceutical Industries was hit with an antitrust class action Friday in New Jersey District Court in relation to its multiple sclerosis drug, Copaxone. The suit contends that Teva used coercive tactics to switch the market from 20mg to 40mg to suppress generic competition. The complaint was filed by Seeger Weiss; Wexler Boley & Elgersma; and Rupp Baase Pfalzgraf Cunningham. Counsel have not yet appeared for the defendants. The case is 2:22-cv-01345, Labor-Management Healthcare Fund v. Teva Pharmaceuticals Industries Ltd. et al. Stay up on the latest deals and litigation with the new Radar.  


This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]